Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biotechnology company, Monaday unveiled new preclinical and clinical data on icovamenib at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025 Conference in Amsterdam.
The findings highlight icovamenib's potential as a groundbreaking therapy for beta-cell restoration, enhancing insulin secretion and sustaining glycemic improvements beyond treatment.
According to Biomea Fusion CEO Thomas Butler, icovamenib demonstrated a significant and lasting increase in C-peptide production, an indicator of endogenous insulin production.
These results reinforce earlier findings that the drug could help patients with impaired beta-cell function regain control of their diabetes. The investigational menin inhibitor is designed to restore pancreatic beta-cell mass and function—key factors in diabetes progression—potentially modifying the disease rather than just managing symptoms.
At ATTD 2025, Biomea Fusion presented key data, including a large-scale analysis of C-peptide levels in icovamenib-treated patients, showing sustained improvements even three months post-treatment. An oral glucose tolerance test (OGTT) further validated the drug's impact on beta-cell insulin secretion, with patients experiencing a 53 percent increase in C-peptide index levels over 26 weeks.
Additionally, icovamenib enhanced the effectiveness of GLP-1-based therapies, potentially allowing for lower doses and improved tolerability.
Medical experts have recognized icovamenib's potential to address beta-cell dysfunction, a root cause of diabetes.
BMEA is currently trading at $2.89, up $0.02 or 0.87 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.